BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11724351)

  • 1. Doxorubicin-formaldehyde conjugate, doxoform: induction of apoptosis relative to doxorubicin.
    Burke PJ; Koch TH
    Anticancer Res; 2001; 21(4A):2753-60. PubMed ID: 11724351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines.
    Taatjes DJ; Fenick DJ; Koch TH
    Chem Res Toxicol; 1999 Jul; 12(7):588-96. PubMed ID: 10409398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth inhibition, nuclear uptake, and retention of anthracycline-formaldehyde conjugates in prostate cancer cells relative to clinical anthracyclines.
    Taatjes DJ; Koch TH
    Anticancer Res; 1999; 19(2A):1201-8. PubMed ID: 10368676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
    Park SJ; Wu CH; Safa AR
    Anticancer Res; 2004; 24(1):123-31. PubMed ID: 15015586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
    Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
    Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells.
    Ling YH; Priebe W; Perez-Soler R
    Cancer Res; 1993 Apr; 53(8):1845-52. PubMed ID: 8467504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells.
    Burke PJ; Kalet BT; Koch TH
    J Med Chem; 2004 Dec; 47(26):6509-18. PubMed ID: 15588086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrasmall gold-doxorubicin conjugates rapidly kill apoptosis-resistant cancer cells.
    Zhang X; Chibli H; Mielke R; Nadeau J
    Bioconjug Chem; 2011 Feb; 22(2):235-43. PubMed ID: 21189001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines.
    Crawford KW; Bowen WD
    Cancer Res; 2002 Jan; 62(1):313-22. PubMed ID: 11782394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
    Szmigielska-Kaplon A; Smolewski P; Najder M; Robak T
    Ann Hematol; 2002 Sep; 81(9):508-13. PubMed ID: 12373351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcl-2 and mdr-1 gene expression during doxorubicin-induced apoptosis in murine leukemic P388 and P388/R84 cells.
    Ramachandran C; You W; Krishan A
    Anticancer Res; 1997; 17(5A):3369-76. PubMed ID: 9413174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of a phenoxazine compound, 2-amino-4,4alpha-dihydro-4alpha,7-dimethyl-3H-phenoxazine-3-one against human B cell and T cell lymphoblastoid cell lines: induction of mixed types of cell death, apoptosis, and necrosis.
    Koshibu-Koizumi J; Akazawa M; Iwamoto T; Takasaki M; Mizuno F; Kobayashi R; Abe A; Tomoda A; Hamatake M; Ishida R
    J Cancer Res Clin Oncol; 2002 Jul; 128(7):363-8. PubMed ID: 12136250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells.
    Burke PJ; Koch TH
    J Med Chem; 2004 Feb; 47(5):1193-206. PubMed ID: 14971899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of apoptosis in human T-cells by organomercuric compounds: a flow cytometric analysis.
    Shenker BJ; Datar S; Mansfield K; Shapiro IM
    Toxicol Appl Pharmacol; 1997 Apr; 143(2):397-406. PubMed ID: 9144456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
    Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
    J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidoxoform: a hydrolytically more stable anthracycline-formaldehyde conjugate toxic to resistant tumor cells.
    Taatjes DJ; Fenick DJ; Koch TH
    J Med Chem; 1998 Apr; 41(8):1306-14. PubMed ID: 9548820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells.
    Hopkins-Donaldson S; Yan P; Bourloud KB; Muhlethaler A; Bodmer JL; Gross N
    Oncogene; 2002 Sep; 21(39):6132-7. PubMed ID: 12203125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231.
    Aroui S; Brahim S; De Waard M; Bréard J; Kenani A
    Cancer Lett; 2009 Nov; 285(1):28-38. PubMed ID: 19523755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
    Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
    Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteinase-3, a serine protease which mediates doxorubicin-induced apoptosis in the HL-60 leukemia cell line, is downregulated in its doxorubicin-resistant variant.
    Wu CH; Gordon J; Rastegar M; Ogretmen B; Safa AR
    Oncogene; 2002 Aug; 21(33):5160-74. PubMed ID: 12140766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.